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Objective: This study aimed to describe self‐reported patterns of use and effects of lysergic
acid diethylamide (LSD) analogues (AL‐LAD, 1P‐LSD, and ETH‐LAD) and the characteristics of
those who use them.
Methods: An anonymous self‐selected online survey of people who use drugs (Global Drug
Survey 2016; N = 96,894), which measured perceived drug effects of LSD and its analogues.
Results: Most LSD analogue users (91%) had also tried LSD. The proportion of U.K. and U.S.
respondents reporting LSD analogue use in the last 12 months was higher than for LSD only. LSD
analogue users described the effects as psychedelic (93%), over half (55%) obtained it online, and
almost all (99%) reported an oral route of administration. The modal duration (8 hr) and time to
peak (2 hr) of LSD analogues were not significantly different from LSD. Ratings for pleasurable
high, strength of effect, comedown, urge to use more drugs, value for money, and risk of harm
following use were significantly lower for LSD analogues compared with LSD.
Conclusions: LSD analogues were reported as similar in time to peak and duration as LSD but
weaker in strength, pleasurable high, and comedown. Future studies should seek to replicate
these findings with chemical confirmation and dose measurement.
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Since the first use of lysergic acid diethylamide (LSD) in 1943 by Albert
Hofmann (Hofmann, 1980), many similarly structured compounds have
emerged such as ALD‐52, AL‐LAD (or Aladdin), ETH‐LAD, PRO‐LAD,
LSZ, and 1P‐LSD, to name just a few (Brandt et al., 2017; Brandt
et al., 2016; Peyton & Shulgin, 1994; Watts, Mailman, Lawler, Neve,
& Nichols, 1995). The increased speed emergence of these new
psychoactive substances (NPS) is partially driven by legislative
processes chasing a synthesise–proscribe–synthesise model (Reuter
& Pardo, 2017). For example, 1P‐LSD use increased in popularity in
the UK following prohibition of LSZ and AL‐LAD in 2015 (Brandt
et al., 2016). Since May 2016, the UK Psychoactive Substances Act
prohibited the supply of 1P‐LSD and any other compounds deemed
to cause a “psychoactive effect” (Reuter & Pardo, 2017). Other
countries now have similar blanket bans on all “psychoactive”
substances (such as Ireland, Poland, Romania, and Australia; seewileyonlinelibrary.com/Barratt, Seear, & Lancaster, 2017) or on analogues of psychoactive
substances (United States; see Kau, 2008). Although the effectiveness
of these policies is yet to be fully established, they may result in a shift
in purchase from “head shops” or high street shops to surface web
vendors, cryptomarkets, and into “street” markets (as discussed in
Barratt & Lenton, 2017; Reuter & Pardo, 2017). The use of LSD
analogues including 1P‐LSD has been recently reported amongst
nightclub attendees in the United States (Palamar, Acosta, Sherman,
Ompad, & Cleland, 2016), and social media and cryptomarket
monitoring studies have also recently detected discussion of this class
of drugs (Van Hout & Hearne, 2017; Vigna et al., 2016).
LSD analogues and LSD share the same lysergic backbone.
However, they present slight variations in their chemical structure,
such as AL‐LAD's modification at the N6 position (Brandt et al.,
2017). These lysergide derivatives act as an agonist of the 5‐HT2A
receptor (Brandt et al., 2016), generally considered the mediator of
hallucinogenic effects behaviourally and subjectively (Geyer &Copyright © 2017 John Wiley & Sons, Ltd.journal/hup 1 of 6
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administration of hallucinogens to humans for research purposes:
There is an unknown potential for harm associated with this class of
drugs, and the subjectivity of individuals' responses can vary
significantly. Therefore, animal behavioural models are useful for
investigating the pharmacology of these drugs. Hallucinogenic effects
can be illustrated by measuring the head twitch response in mice
(Hanks & Gonzalez‐Maeso, 2013). The head twitch response in mice
is a side‐to‐side head movement elicited only by a hallucinogenic
5‐HT2A agonist, which effectively discriminates between hallucino-
genic and non‐hallucinogenic 5‐HT2A agonists. This response was
found for mice that had been administered 1P‐LSD (Brandt et al.,
2016), indicating that 1P‐LSD is indeed likely to have hallucinogenic
effects in humans. Although lab‐based evidence for human experience
of 1P‐LSD does not exist, detailed experiences reported by users
(see Psychonaut Wiki, 2016a) include auditory and visual perceptual
alterations following the consumption of 1P‐LSD.
Research on mice regarding the potency of these compounds
compared to LSD (ED50 = 132.8 nmol/kg) indicated 1P‐LSD
(ED50 = 349.6 nmol/kg) to be 38% the potency of LSD (Brandt et al.,
2016), AL‐LAD slightly less potent (ED50 = 174.9 nmol/kg), and LSZ
equipotent (ED50 = 114.2 nmol/kg; Brandt et al., 2017). These varying
potencies shown in mice do not reflect reported dosages in humans.
The typical dosage of LSD is approximately 150 μg, however, the
dosage of AL‐LAD ranged between 80 and 160 μg (Shulgin & Shulgin,
1997), LSZ between 100 and 300 μg (Erowid, 2014), and 1P‐LSD
between 50 and 300 μg (Psychonaut Wiki, 2016a). The duration of
the effects of LSD analogues (AL‐LAD and LSZ 6–10 hr and 1P‐LSD
8–12 hr; Psychonaut Wiki, 2016a, 2016b, 2016c) is, however,
comparable to that of typical LSD (6–12 hr).
What we currently know about the use of LSD analogues in
humans is based on animal models plus the experience and effect
reports posted to websites and wikis. In this paper, we use an
anonymous web survey to describe the self‐reported effect profile of
LSD analogues, including AL‐LAD, 1P‐LSD, and ETH‐LAD, in humans,
in comparison to the effect profile of the better‐known drug, LSD.
We also compare LSD analogue and LSD user profiles.2 | METHOD
An anonymous online survey on the use of psychoactive substances
was designed and conducted by Global Drug Survey (GDS) (http://
www.globaldrugsurvey.com/archive/GDS2016/) between November
2015 and February 2016. GDS runs the world's biggest drug survey
and is conducted annually, in partnership with global media partners
who promote the survey to their audiences. In 2016, the survey
was translated into 10 languages. GDS enables rapid assessment
and identification of novel drugs as well as new drug trends before
their spread to the wider community (e.g., Kaar et al., 2016; Lawn,
Barratt, Williams, Horne, & Winstock, 2014; Lawn, Borschmann,
Cottrell, & Winstock, 2016). Ethical approval was received from
King's College London (PNM1415‐18). Participation was voluntary,
and no incentives (payments or lotteries) were offered for
participation.A total of 100,711 responses were submitted to GDS. After
preparing the data, 3,817 records were excluded due to data capture
glitches, duplicate entries, reporting no psychoactive drug use at all,
reporting the use of a fake drug, and reported age over 100 years.
Almost one third of the remaining 96,894 responses were from
Germany (n = 29,865, 31%), followed by Switzerland (n = 8,173,
8%), New Zealand (n = 7,633, 8%), UK (n = 6,015, 6%), United States
(n = 5,366, 6%), Netherlands (n = 5,058, 5%), and Australia
(n = 4,931, 5%), with the remaining countries accounting for 31%.
The average age of respondents was 28.7 years (SD = 11.2,
range = 16–95), and the majority were male (64%) with the remain-
ing female (34%), and transgender (1%). The subsample comprised
3,678 respondents who reported LSD analogues or LSD as their last
new drug tried. The average age of the subsample was 23.4 years
(SD = 5.7, range = 16–56), and the majority were male (74%) with
the remaining female (25%), and transgender (1%).
Self‐reported lifetime use and recent (last 12 month) use of LSD
and LSD analogues were collected. The use of LSD analogues was
measured separately for AL‐LAD and also as a category, labelled
“LSD Analogues (e.g., 1P‐LSD and ETH‐LAD).” For this paper,
variables relating to AL‐LAD and LSD Analogues (e.g., 1P‐LSD and
ETH‐LAD) were combined and hereon referred to as “LSD analogues.”
Although it is possible that respondents may have included others, the
three LSD analogues named in the survey were AL‐LAD, 1P‐LSD, and
ETH‐LAD. For both LSD and LSD analogues, profiling information was
collected regarding route of administration (ROA), source of the drug,
and effects such as the type of effect, duration, time to peak, strength
(scored from 1 to 10, 10 = extremely strong), pleasurable high (scored
from 1 to 10, 10 = best ever had), comedown (scored from 1 to 10,
10 = extremely strong), urge to use more drugs (scored from 1 to 10,
10 = extremely strong), negative effects whilst high (scored from 1 to
10, 10 = extremely strong), risk of harm following use of the drug
(scored from 1 to 10, 10 = extremely high risk), and value for money
(scored from 1 to 10, 10 = best experienced), where these drugs
were identified as being the last drug tried for the first time. This
profiling set of variables has been used previously by the GDS group
to profile NPS, including mephedrone (Winstock et al., 2011), the
NBOMe series (Lawn et al., 2014), DMT (Winstock, Kaar, &
Borschmann, 2014), and methoxetamine (Winstock, Lawn, Deluca, &
Borschmann, 2016).
Prior to running the multivariate analyses, missing value analysis
on variables of interest showed no variables with less than 5% missing.
Multicollinearity and singularity were also tested using a Pearson
product moment correlation. All variables correlated in a meaningful
way, ensuring the validity of the statistical analysis used (Tabachnick
& Fidell, 2013). Normality and homoscedasticity assumptions for
multivariate analyses were met. Linearity appeared to be violated;
however, multivariate analysis of variance (MANOVA) is robust to this
violation (Tabachnick & Fidell, 2013), and therefore, conducting a
MANOVA was deemed acceptable. As described more fully in the
results, the univariate assumption of equality of variance was not
met for some variables. MANOVA was conducted to compare
differences between LSD and LSD analogues on effects such as
strength, pleasurable high, negative effects whilst high, comedown,
risk of harm following use, and value for money. Independent
CONEY ET AL. 3 of 6samples t tests were conducted to determine differences in duration
and time to peak. The alpha level was set at .05 and only valid
percentages were used.3 | RESULTS
3.1 | Patterns of use
Amongst the entire sample (N = 96,894), 25,953 (27%) reported use of
LSD compared with 2,349 (2%) that reported use of LSD analogues
(see Table 1). Recent (last 12‐month) LSD use was reported by 13%
of the entire sample (n = 12,491), whereas recent LSD analogue use
was reported by 1% (n = 1,431). Of the 2,202 respondents with
available data who reported ever using LSD analogues, 2,004 (91%)TABLE 1 Recency of LSD and LSD analogue use (%)
LSD LSD analogues
(N = 25,953) (N = 2,349)
Yes, but not in the last 12 months 50% 35%
Yes, in the last 12 months, but not
in the last 30 days
34% 48%
Yes, in the last 30 days, but not in
the last 7 days
11% 12%
Yes, in the last 7 days 5% 5%
Note. Base for percentage is the number of respondents who reported ever
use of LSD or LSD analogues. LSD = lysergic acid diethylamide.
TABLE 2 Demographic characteristics of recent (in the last 12 months) LS
Variables Level (n)
Recent LSD an
N = 1,249
Countryb Germany (29,685) 16% (199
Switzerland (8,173) 1% (18)
New Zealand (7,633) 3% (42)
United Kingdom (6,015) 19% (237
United States (5,366) 17% (217
Netherlands (5,058) 2% (23)
Australia (4,931) 1% (18)
Ethnicity White (84,971) 80% (998
Non‐White (11,923) 20% (251
Age (95,799) M = 23.37, SD
Gender Male (62,583) 81% (1,00
Female (32,587) 18% (217
Transgender (443) 1% (9)
Currently studying Full time (31,482) 44% (542
Part time (8,314) 11% (134
Not studying (54,722) 45% (553
Occupation Professional (23,406) 21% (251
Sales worker (8,111) 13% (151
Labourer (6,726) 12% (140
Manager/administrator (12,775) 8% (97)
Technician/tradesperson (7,888) 11% (129
Community/personal Service (7,787) 10% (117
Clerical workers (8,589) 5% (61)
Machinery workers (1,079) 2% (25)
Never worked (13,129) 17% (212
Note. GDS = Global Drug Survey; LSD = lysergic acid diethylamide.
aLSD analogue group included respondents who reported use of LSD analogu
reported use of LSD in the last 12 months but not LSD analogues.
bResults from the top seven countries in the whole GDS sample are reported hreported lifetime use of LSD. Of the 1,249 with available data who
reported using LSD analogues in the last 12 months, 1,055 (85%) also
reported LSD use in the last 12 months.3.2 | Demographics of LSD analogue users
Comparisons of demographic characteristics were performed between
individuals who reported (a) use of LSD analogues in the last 12 months
and (b) use of LSD in the last 12 months but not LSD analogues (see
Table 2). There was a significantly higher proportion of recent LSD
analogue users in the UK and the United States compared with recent
LSD users. Overall, recent LSD analogue users had a younger mean age
and were more likely to be male compared with recent LSD users.3.3 | Description by those whom an LSD analogue
was “the last new drug tried”
Almost all participants reporting LSD analogues as their last new drug
tried described the effects as mostly psychedelic (LSD/ketamine like;
93%), whereas 2% described it as mostly stimulant (cocaine/amphet-
amine like), 1% mostly cannabis like, and 1% mostly empathogenic
(MDMA/ecstasy like). Additionally 2% of the group described the
effects as “other.” The most common source of LSD analogues was
online (n = 186, 56%), followed by a friend (n = 111, 33%), then a dealer
(n = 28, 8%); these reported sources were significantly different from
the ones reported for LSD, χ(5) = 649.20, p < .001, which was less likely
to be sourced online (n = 260, 8%) and more likely to be sourced from aD and LSD analogue usersa
alogue use
Recent LSD use (excludes
LSD analogue use)
Test for differenceN = 11,055
) 18% (2,002) χ(1) = 3.62, p = .057
4% (413) χ(1) = 17.48, p < .001
5% (528) χ(1) = 5.08, p = .024
) 9% (962) χ(1) = 134.66, p < .001
) 14% (1,574) χ(1) = 8.87, p = .003
3% (272) χ(1) = 1.84, p = .175
2% (188) χ(1) = .46, p = .498
) 78% (8,658) χ(1) = 1.67, p = .196
) 22% (2,379)
= 6.22 M = 24.16, SD = 6.51 t(12164) = 4.11, p < .001
8) 75% (8,131) χ(2) = 30.69, p < .001
) 24% (2,689)
1% (72)
) 40% (4,369) χ(2) = 6.35, p = .042
) 12% (1,256)
) 48% (5,162)
) 24% (2,450) χ(8) = 21.38, p = .006
) 13% (1,362)
) 11% (1,138)
10% (1056)
) 9% (957)
) 10% (979)
6% (657)
2% (157)
) 15% (1,562)
es in the last 12 months, and the LSD group included respondents who
ere.
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swallowing as the common ROA (n = 278, 83%) whereas the 17% of
other ROA commonly reported “sublingual,” “blotter,” and “tab,” which
are all oral routes. Only one participant reported snorting and one
other reported injecting. Reported ROA for LSD did not significantly
differ from LSD analogues ROA, χ(5) = 7.69, p = .174.3.4 | Comparison of effects of LSD and LSD
analogues
The modal duration of effect for both LSD and LSD analogues was
8 hr. The results indicated no significant difference in duration
between LSD and LSD analogue groups, t(443) = 1.50, p = .134. The
modal time to peak was 2 hr for both LSD and LSD analogues. There
were no significant difference in mean times to peak for LSD and
LSD analogues, t(3601) = .85, p = .398.
A MANOVA was conducted to compare LSD (n = 3,015) and LSD
analogues (n = 306) on pleasurable high, strength of effect, negative
effects whilst high, comedown, urge to use more, value for money,
and risk of harm following use of the drug. The assumption of equality
of variance was not met for pleasurable high, F(1, 3319) = 7.37,
p = .007, negative effects when high, F(1, 3319) = 10.41, p = .001,
comedown, F(1, 3319) = 4.94, p = .026, urge to use more drugs, F(1,
3319) = 13.39, p < .001, and risk of harm, F(1, 3319) = 47.85,
p < .001. The MANOVA yielded significant findings on the combined
variables measuring the effects of the last new drug used, F(7,
3313) = 4.74, p < .001, ἠ2 = .01, power ≥ 1. Results showed that ratings
of LSD did not differ from ratings of LSD analogues on negative effects
when high, F(1, 3319) = 0.81, p = .368. However, ratings of LSD were
significantly higher than ratings of LSD analogues on pleasurable high,
F(1, 3319) = 5.50, p = .019, ἠ2 = .01, power = .65, strength of effect,
F(1, 3319) = 5.51, p = .019, ἠ2 = .01, power = .65, comedown, F(1,
3319) = 5.37, p = .021, ἠ2 = .01, power = .64, urge to use more drugs,
F(1, 3319) = 3.89, p = .049, ἠ2 = .01, power = .50, value for money, F(1,
3319) = 10.78, p = .001, ἠ2 = .01, power = .91, and risk of harm, F(1,
3319) = 27.32, p < .001, ἠ2 = .01, power = .99; see Table 3).TABLE 3 Drug effect ratings by LSD and LSD analogues (mean, SD)
Drug effect
Last new drug tried
MANOVA
p value
LSD
(n = 3,015)
LSD analogues
(n = 306)
Pleasurable high 7.88 (1.98) 7.60 (1.74) .019
Strength of effect 7.85 (1.97) 7.57 (1.94) .019
Negative effects
when high
2.97 (2.55) 2.83 (2.23) .368
Comedown 3.32 (2.78) 2.93 (2.61) .021
Urge to use more
drugs when using
1.45 (2.27) 1.19 (1.99) .049
Value for money 7.97 (2.29) 7.52 (2.29) .001
Risk of harm
following use
2.44 (2.54) 1.66 (1.91) <.001
Note. Effect ratings were on a scale of 1 (lowest) to 10 (highest).
LSD = lysergic acid diethylamide; MANOVA = multivariate analysis of
variance.4 | DISCUSSION
To our knowledge, this paper is the first to describe patterns of use and
self‐reported effects of LSD analogues (AL‐LAD, 1P‐LSD, and ETH‐
LAD) in humans. In this sample, “typical” users of these analogues were
males aged in their mid‐20s, identifying as “White,” who were mostly
full‐time students or employed. These characteristics were similar to
the demographics of other psychedelic drug users (e.g., Lawn et al.,
2014; Winstock et al., 2014), although they may also reflect the bias
of people inclined to complete the GDS. Nonetheless, some differences
were identified between LSD and LSD analogue users. There were
significantly higher proportions of respondents from the UK and the
United States reporting recent LSD analogue use compared to recent
LSD only use. It should be noted that these survey data were collected
during a period when 1P‐LSD was still legal in the UK, therefore this
trend may be subject to change in future years. The majority of partic-
ipants who had used LSD analogues reported that they had obtained
LSD analogues online, which significantly differed from methods used
to obtain LSD, matching with previous reports on the widespread avail-
ability of NPS online (Brandt, King, & Evans‐Brown, 2014; Van Buskirk,
Naicker, Roxburgh, Bruno, & Burns, 2016). Themost common ROAwas
oral, and the majority of participants reported the type of effect as
psychedelic (LSD/ketamine like), which did not significantly differ from
LSD. The modal duration of effect reported for LSD analogues (8 hr) as
well as the time to peak (2 hr) was the same as LSD. A comparison of the
reports on perceived effects of LSD analogues and LSD showed that
LSD was rated significantly higher for pleasurable high, strength, urge
to use more drugs, value for money, risk of harm following use, and
comedown. These results suggest that LSD analogues are “weaker”
versions of LSD. This result is consistent with animal research showing
LSD analogues such as 1P‐LSD having a lower potency than LSD in
mice (Brandt et al., 2016).
This study has several limitations. The main weakness of this study
was the possible drug reporting inaccuracies, both intentional and
unintentional as well as manufacturer mislabelling. It is possible that
users led to believe they were taking LSD were in fact consuming
one of its analogues and vice versa. Also, it is plausible that the sub-
stances taken were unrelated to LSD such as those from the NBOMe
series (Caldicott, Bright, & Barratt, 2013; Martins et al., 2017 under
review). Future studies should seek to replicate these findings with
chemical confirmation. In addition, future studies should investigate
harms of LSD analogues, both short term and long term. Measuring
additional detail regarding the experience such as dosage and whether
or not other drugs were consumed concurrently should be considered
to gain a better understanding of LSD analogue effects in humans. A
further limitation is that the survey sample was self‐selected, and
therefore, not necessarily representative of a wider population of
psychedelic users.5 | CONCLUSION
This is the first study to describe the self‐reported effect profile of LSD
analogues, including AL‐LAD, 1P‐LSD, and ETH‐LAD, in humans. The
profile of LSD analogues was reported to be very similar to LSD in
CONEY ET AL. 5 of 6relation to duration, time to peak, and ROA (oral). However, LSD
analogues were considered weaker in regard to strength, pleasurable
high, and comedown. Future research should monitor and test the
substances subject to investigation and seek to replicate and confirm
these initial findings.
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